Ribonucleic Acid (RNA) Microarray Market Global Report 2026

The ribonucleic acid (RNA) microarray market size has grown strongly in recent years. It will grow from $1.61 billion in 2025 to $1.77 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to growth in genomic research and gene expression studies, development of dna and rna hybridization based microarray platforms, increasing adoption of clinical diagnostics using gene expression profiling, expansion of pharmaceutical research using transcriptomic data, rising demand for high throughput molecular biology techniques.

The ribonucleic acid (RNA) microarray market size is expected to see strong growth in the next few years. It will grow to $2.52 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to integration of AI driven gene expression interpretation tools, increasing demand for personalized medicine and biomarker discovery, expansion of multi omics and systems biology research, rising adoption of automated and high throughput microarray platforms, growth in cloud enabled genomic data analytics and storage solutions. Major trends in the forecast period include integration of AI powered gene expression analysis platforms for large scale rna microarray data interpretation, increasing adoption of cloud based microarray data storage and bioinformatics pipelines, expansion of high density microarray chips for multi transcriptome profiling, growing use of automated microarray scanning and hybridization systems, rising demand for precision medicine driven gene expression profiling using rna microarrays.

The growing adoption of personalized medicine is expected to drive the expansion of the ribonucleic acid (RNA) microarray market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatments and clinical decisions to individual patients based on their genetic characteristics, lifestyle, and environmental influences. The adoption of personalized medicine is increasing due to advancements in genomics and biotechnology, which enable more accurate diagnoses and targeted therapies based on a patient’s unique genetic profile. Ribonucleic acid (RNA) microarrays support personalized medicine by simultaneously analyzing the expression levels of thousands of genes, enabling clinicians to identify disease-specific molecular signatures and customize treatments according to an individual’s biological profile for more precise and effective therapy selection. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to 6 approvals in 2022, representing an increase of 10 personalized treatment approvals. Therefore, the growing adoption of personalized medicine is driving the growth of the ribonucleic acid (RNA) microarray market.

The increasing prevalence of cancer is expected to propel the growth of the ribonucleic acid (RNA) microarray market going forward. Cancer prevalence refers to the total number of individuals living with cancer within a defined population during a specific period or at a particular point in time. The increasing prevalence of cancer is mainly attributed to the aging global population, as older individuals are more likely to accumulate genetic mutations and develop malignant diseases over time. Ribonucleic acid (RNA) microarrays contribute to cancer research and clinical oncology by enabling high-throughput gene expression profiling, helping researchers and clinicians identify tumor-specific biomarkers, better understand disease mechanisms, and assess treatment responses at the transcriptomic level. For instance, in January 2023, according to the American Cancer Society, a US-based cancer surveillance and epidemiology organization headquartered in Atlanta, 1,958,310 new cancer cases were reported in 2023, compared to 1,918,030 cases in 2022, reflecting an increase of approximately 40,280 new cases year over year. Therefore, the increasing prevalence of cancer is driving the growth of the ribonucleic acid (RNA) microarray market.

The increasing government funding for biotechnology research initiatives is expected to propel the growth of the ribonucleic acid (RNA) microarray market going forward. Biotechnology research initiatives are structured programs and projects supported by governments, research institutions, or private organizations to advance the development and application of biological and molecular technologies across healthcare, agriculture, and industrial sectors. Government investment in biotechnology research is increasing due to the growing need to address complex health conditions such as cancer and genetic disorders, which require advanced scientific research and innovative technologies for improved diagnosis, treatment, and prevention. Government funding for ribonucleic acid (RNA) microarray research supports advanced genomic studies, facilitates the development of high-throughput gene expression technologies, enhances cancer diagnostics and biomarker discovery, and accelerates the translation of molecular research into clinical practice. For instance, in May 2023, according to the Earlham Institute (EI), a UK-based research institute, it received $39.7 million (拢31.4 million) from the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), to support a five-year program focused on advancing research, developing new technologies, and fostering innovation and impact. Therefore, the increasing government funding for biotechnology research initiatives is driving the growth of the ribonucleic acid (RNA) microarray market.

Major companies operating in the ribonucleic acid (RNA) microarray market report are Thermo Fisher Scientific Inc., LGC Limited, Merck KGaA, Danaher Corporation, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Arraystar Inc., Takara Bio Inc., Macrogen Inc., CapitalBio Technology, Genotypic Technology Pvt Ltd., CD Genomics, Phalanx Biotech Group, LC Sciences, Enzo Biochem Inc., Oxford Gene Technology, Bioneer Corporation, Savyon Diagnostics.

North America was the dominating region in the ribonucleic acid (RNA) microarray market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid (RNA) microarray market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (RNA) microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.